1. Matter, L, et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after introduction of MMR mass vaccination. European Journal of Epidemiology 1997; 13: 61–63.
2. Janaszek, W, Gut, W, Gay, NJ. The epidemiology of measles in Poland: prevalence of measles virus antibodies in the population. Epidemiology and Infection 2000; 125: 385–392.
3. Osborne, K, et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. International Journal of Epidemiology 2000; 29: 362–368.
4. Gabutti, G, et al. Epidemiology of measles, mumps and rubella in Italy. Epidemiology and Infection 2002; 129: 543–550.
5. Chiu, H-H, et al. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Journal of Medical Virology 1997; 51: 32–35.
6. Gilbert, GL, et al. Impact of the Australian measles control campaign on immunity to measles and rubella. Epidemiology and Infection 2001; 127: 297–303.
7. Kim, S-S, et al. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity. Vaccine 2004; 23: 290–297.
8. Osborne, K, Weinburg, J, Miller, E. The European Seroepidemiology Network. Eurosurveillance 1997; 2: 29–31.
9. Ratnam, S, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralisation test for detection of measles virus antibody. Journal of Clinical Microbiology 1995; 33: 811–815.
10. Hesketh, L, et al. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. Journal of Virological Methods 1997; 66: 51–59.
11. Andrews, N, et al. The European Sero-Epidemiological Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127–143.
12. Kafatos, G, Andrews, N, Nardone, A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 5022–5027.
13. Dopatka, HD, Giesendorf, B. Single point quantification of antibody by ELISA without need of a reference curve. Journal of Clinical and Laboratory Analysis 1992; 6: 417–422.
14. Tischer, A, Gerike, E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18: 1382–1392.
15. Anon. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ‘Text on Validation of Analytical Procedures Q2a’ (http://www.ich.org/LOB/media/MEDIA417.pdf). Accessed 6 November 1996. 16. Anon. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ‘Validation of Analytical Procedures: Methodology Q2b’ (http://www.ich.org/LOB/media/MEDIA417.pdf). Accessed 6 November 1996.
18. Örvell, C, et al. Characterisation of genotype specific epitopes of the HN protein of mumps virus. Journal of General Virology 1997; 78: 3187–3193.
19. Muhlemann, K. The molecular epidemiology of mumps virus. Infection Genetics and Evolution 2004; 4: 215–219.
20. Albrecht, P, Herrmann, K, Burns, GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. Journal of Virological Methods 1981; 3: 251–260.
21. Chen, RT, et al. Measles antibody: reevaluation of protective titres. Journal of Infectious Diseases 1990; 162: 1036–1042.
22. Lee, MS, et al. Protective titres of measles neutralising antibody. Journal of Medical Virology 2000; 62: 511–517.
23. Berger, R, Just, M. Comparison of five different tests for mumps antibodies. Infection 1980; 8: 180–183.
24. Sakata, H, Hishiyama, M, Sugiura, A. Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines. Journal of Clinical Microbiology 1984; 19: 21–25.
25. Linde, GA, Granström, M, Örvell, C. Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity. Journal of Clinical Microbiology 1987; 25: 1653–1658.
26. Pipkin, PA, et al. Assay of humoral immunity to mumps virus. Journal of Virological Methods 1999; 79: 219–225.
27. Fedova, D, et al. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test. Journal of Hygiene, Epidemiology, Microbiology and Immunology 1987; 31: 409–422.
28. Christensen, B, Böttiger, M. Methods for screening the naturally aquired and vaccine-induced immunity to the mumps virus. Biologicals 1990; 18: 213–219.
29. Frankova, V, et al. Contribution to laboratory diagnosis of mumps and parainfluenza. Acta Virologica 1988; 32: 503–514.
30. Harmsen, T, et al. Comparison of neutralization enzyme immunoassay and enzyme-linked immuno-sorbent assay for evaluation of the immune status of mumps vaccinated children. Journal of Clinical Microbiology 1992; 30: 2139–2144.
31. Skendzel, LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170–174.
32. Matter, L, Kogelschatz, K, Germann, D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. Journal of Infectious Diseases 1997; 175: 749–755.
33. Davidkin, I, et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000; 18: 3106–3112.